Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Rises By 91.3%

TScan Therapeutics, Inc. (NASDAQ:TCRX) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 419,700 shares, an increase of 91.3% from the March 31st total of 219,400 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 193,600 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TCRX shares. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th. Wedbush reissued an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Letko Brosseau & Associates Inc. purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $83,000. Pale Fire Capital SE purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $42,000. abrdn plc purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at $1,166,000. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of TScan Therapeutics in the 1st quarter valued at $139,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Price Performance

NASDAQ:TCRX traded up $0.03 during mid-day trading on Friday, hitting $7.32. 92,052 shares of the stock traded hands, compared to its average volume of 210,320. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $5.82. The company has a market cap of $350.50 million, a PE ratio of -3.87 and a beta of 0.90. TScan Therapeutics has a 12-month low of $1.62 and a 12-month high of $9.00. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The business had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $2.94 million. On average, analysts expect that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.